$VBIV problem is share structure; shares Outstanding:: 178.26M Float 107.11M Market Cap: 291M imo they could hit the offering in this upcoming week, but it could also provide some oppurtunity. The Company will require significant additional funds to conduct clinical and non-clinical trials, achieve regulatory approvals, and, subject to such approvals, commercially launch its products. The Company plans to finance its future operations with existing cash reserves. Additional financing may be obtained from the issuance of equity securities, the issuance of additional debt, structured asset financings, and/or revenues from potential business development transactions, if any. In September 2019, the Company closed an underwritten public offering of 80,500,000 common shares at a price of $0.50 per share for total gross proceeds of $40,250. The Company incurred $2,835 of share issuance costs related to the offering resulting in net cash proceeds of $37,415. secfilings.nasdaq.com/filin...
  • 2
  • 10